Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ORIC ORIC Pharmaceuticals, Inc. daily Stock Chart
ORIC [NASD]
ORIC Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)- Insider Own0.40% Shs Outstand28.75M Perf Week-15.03%
Market Cap698.62M Forward P/E- EPS next Y-2.14 Insider Trans0.00% Shs Float16.21M Perf Month-23.82%
Income- PEG- EPS next Q-0.34 Inst Own59.90% Short Float15.46% Perf Quarter-
Sales- P/S- EPS this Y-25.80% Inst Trans- Short Ratio8.21 Perf Half Y-
Book/sh- P/B- EPS next Y11.90% ROA- Target Price42.75 Perf Year-
Cash/sh2.76 P/C8.80 EPS next 5Y- ROE- 52W Range23.50 - 40.67 Perf YTD-5.70%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-40.20% Beta-
Dividend %- Quick Ratio16.80 Sales past 5Y- Gross Margin- 52W Low3.49% ATR2.92
Employees57 Current Ratio16.80 Sales Q/Q- Oper. Margin- RSI (14)32.56 Volatility9.80% 9.76%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.13 Prev Close24.30
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume305.25K Price24.32
Recom1.60 SMA20-22.82% SMA50-23.17% SMA200-21.91% Volume3,313 Change0.08%
May-19-20Initiated JP Morgan Overweight $40
May-19-20Initiated Jefferies Buy $40
May-19-20Initiated Guggenheim Buy $45
May-19-20Initiated Citigroup Neutral $35
Jun-22-20 09:00AM  
ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting II
GlobeNewswire -6.95%
Jun-09-20 04:15PM  
ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors
GlobeNewswire -5.15%
May-27-20 06:30AM  
ORIC Pharmaceuticals Announces Five Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II
GlobeNewswire
May-26-20 06:30AM  
ORIC Pharmaceuticals to Present at the Jefferies 2020 Global Healthcare Conference
GlobeNewswire
May-20-20 04:15PM  
ORIC Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results
GlobeNewswire -9.75%
Apr-28-20 04:30PM  
ORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
GlobeNewswire
Apr-27-20 04:30PM  
ORIC Pharmaceuticals Presents Preclinical Data on CD73 Inhibitor at the American Association for Cancer Research (AACR) Virtual Annual Meeting
GlobeNewswire
Apr-23-20 08:56PM  
ORIC Pharmaceuticals Announces Pricing of Initial Public Offering
GlobeNewswire
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
open in yahoo | open in reuters | open in google